ArticleJournal of ophthalmic inflammation and infection2024
Occlusive retinal vasculitis associated with intravitreal Faricimab injections.
Article in Journal of ophthalmic inflammation and infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Clinical characteristics and outcomes of intraocular inflammation following intravitreal faricimab for neovascular age-related macular degeneration: a single-centre retrospective study.Eye (London, England) · 2026Article
- Efficacy and Safety of Intravitreal Faricimab in Age-Related Macular Degeneration-A Review.Journal of clinical medicine · 2025Review
- Central Retinal Artery Occlusion After Intravitreal Injection of Faricimab: A Case Report.Cureus · 2025Article
- Inflammation and Occlusive Retinal Vasculitis Post Faricimab.JAMA ophthalmology · 2025Article
- Clinical Outcomes Following a Switch of Therapy to Faricimab in Patients Affected by Neovascular Age-Related Macular Degeneration.Journal of clinical medicine · 2025Article
- Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe describe a case of occlusive vasculitis associated with intravitreal Faricimab (Vabysmo) injections.
methodsA retrospective case report.
resultsA 52-year old man treated with monthly Faricimab injections for diabetic macula oedema presented with sudden reduced vision, new retinal hemorrhages, significant retinal vascular occlusions and ischemia. After screening for differential diagnoses was unremarkable, the patient was treated with oral and intravitreal steroid therapy under which the occlusive vasculitis was stabilized.
conclusionOcclusive vasculitis, though rare, is a potential complication of Faricimab therapy. Comprehensive reporting and large-scale analyses are essential to better understand and manage this adverse event.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.